Pacira BioSciences, Inc. Share Price & Technical Analysis
PCRX · $23.35 (-0.55%)
Healthcare / Drug Manufacturers - Specialty & Generic
$23.35
-0.55%
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indi…
Price chart
Seasonality
May has 1 positive and 4 negative years (last 5 years shown)
-13% return in May, -1% avg return in past 3 year May month.
-10% return in 2026, -3% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -21% | 7% | 5% | 13% | -13% | – | – | – | – | – | – | – | -10% |
| 25 | 38% | -6% | 4% | 9% | -3% | -8% | -12% | 26% | -3% | -17% | 10% | 10% | 48% |
| 24 | -3% | -9% | -2% | -11% | 15% | -6% | -28% | -25% | -1% | 11% | 1% | 11% | -49% |
| 23 | 1% | 9% | -5% | 11% | -16% | 6% | -9% | -3% | -14% | -8% | -3% | 23% | -8% |
| 22 | 4% | 6% | 14% | -2% | -15% | -8% | -2% | -6% | 2% | -4% | -8% | -20% | -40% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Neutral
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled doses of cold temperature to targeted nerves to produce neurolytic block that interrupts the pain-transmitting signals of a peripheral nerve. It also develops PCRX-201, a novel gene therapy vector platform enabling local administration of genetic medicines with the potential to treat large prevalent diseases like osteoarthritis. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product for use in animals. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Brisbane, California.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$887.69M
P/E ratio
173.54
52W high
$27.64
52W low
$18.80
Volume
8,57,902
Beta
0.32
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Pacira BioSciences, Inc. share price today?
- Pacira BioSciences, Inc. (PCRX) last traded around $23.35 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does PCRX have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for PCRX. Download the app for real-time alerts.
- How can I analyze Pacira BioSciences, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.